Evaluation of safety and efficacy of multiple intravenous and intraosseous doses of foetal liver-derived mesenchymal stem cells in children with severe osteogenesis imperfecta
The BOOST2B trial has been approved by the regulatory agencies in India and is ongoing. It is the first clinical trial designed to evaluate IO administration of MSCs as a potential therapy for OI. Here, we describe the BOOST2B clinical trial protocol. The long-term data on safety and efficacy will be reported once completed.
Authors
- Shyamkumar Nidugala Kesava
- Lilian Walther–Jallow (ORCID: https://orcid.org/0000-0001-8731-1917)
- Vrisha Madhuri (ORCID: https://orcid.org/0000-0003-4494-222X)
- Vikram Mathews (ORCID: https://orcid.org/0000-0001-9417-2353)
- Cecilia Götherström (ORCID: https://orcid.org/0000-0003-3782-0048)
- Thomas V. Paul (ORCID: https://orcid.org/0000-0003-3315-341X)
- Annika Goos
- Sowmya Ramesh (ORCID: https://orcid.org/0000-0002-4086-9603)
Institutions
- Christian Medical College, Vellore (IN)
- Karolinska Institutet (SE)
- Institute for Stem Cell Biology and Regenerative Medicine (IN)
Publication Details
- Journal
- Bone & Joint Open
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1302/2633-1462.63.bjo-2024-0115.r1
- Primary Topic
- Connective tissue disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00